What Is NIH TABA?

Mike Hull • September 4, 2026

NIH Technical and Business Assistance—commonly called TABA—is designed to help SBIR and STTR recipients address product-development and commercialization needs that are often outside the core scientific aims of the award.

How Much Taba Funding Is Available?

Under NIH policy applicable to SBIR/STTR awards and supplements made on or after April 13, 2026, recipients may request up to $6,500 per Phase I project across all years and up to $50,000 per Phase II project across all years. NIH also describes up to $50,000 for a Phase IIB Strategic Breakthrough project. Availability can depend on the specific Institute, Center, and funding opportunity

What Can Taba Support?

NIH identifies a broad range of eligible technical and business activities. The best use is usually a clearly defined commercialization problem that requires expertise the company does not already have.


  • Market research and market validation
  • Regulatory planning
  • Manufacturing planning
  • Intellectual-property strategy and protections
  • Product sales and commercialization assistance
  • Cybersecurity assistance
  • Technical and business literature or databases
  • Participation in NIH I-Corps or similar training
  • Other activities consistent with reducing technical or commercialization risk

How Is Taba Requested?

NIH encourages companies to request TABA in the original SBIR/STTR application. The request is identified on the SBIR/STTR Information Form, the cost is labeled 'Technical Assistance' under Other Direct Costs, and the budget justification should explain the need and proposed use.


NIH also states that post-award TABA may be requested through an administrative supplement, subject to the discretion and prior-approval process of the awarding Institute or Center.

Taba Is Not Generic Overhead

A strong TABA request connects an outside activity to a specific development decision. 'Commercialization consulting' is vague. 'Develop a U.S. regulatory pathway assessment, competitor matrix, customer-discovery plan, and commercialization milestones to inform Phase II development' is much easier to evaluate.

BYB Takeaway

TABA is most valuable when it solves a defined commercialization problem and produces a concrete deliverable that improves the company's next technical, regulatory, market, or financing decision.

BYB can help founders define commercialization work packages that are specific enough to be useful and fundable.

Source Notes

NIH SEED, Technical and Business Assistance: https://seed.nih.gov/product-development-support/technical-business-assistance

NIH Notice NOT-OD-26-075, Policy changes to SBIR and STTR Discretionary TABA: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-26-075.html

How to Commercialize University Research

By Mike Hull • September 14, 2026
Commercialization requires a second layer of work: translating the discovery into a defined use case, protectable asset, development plan, evidence package, and funding strategy that a customer, licensee, investor, or strategic partner can act on.

What Is a Biotech Commercialization Plan?

By Mike Hull • September 13, 2026
It is the operating logic that explains how a scientific asset can move from its current state to a product that can be funded, licensed, approved, adopted, reimbursed, partnered, or sold.

How Much Validation Do You Need Before Raising Capital?

By Mike Hull • September 12, 2026
There is no universal amount of validation required before a biotech company raises capital. Investors fund risk, so a company does not need every question answered.

License Your Technology or Start a Biotech Company?

By Mike Hull • September 11, 2026
For university inventors, one of the most important commercialization decisions is whether to license the technology directly to an established company or form a startup to develop it further.

The Bootstrap Score™

By Mike Hull • September 10, 2026
The Bootstrap Score™ is a practical framework for asking a more useful question: how much of the commercial risk has been reduced around the science?

The Commercialization Gap™

By Mike Hull • September 9, 2026
A paper can establish an important scientific finding, while a buyer, investor, regulator, licensee, or strategic partner may still see substantial unanswered risk.

The Valley of Dilution™

By Mike Hull • September 8, 2026
There is another risk that receives less attention—the Valley of Dilution™. It occurs when a company raises expensive equity before key uncertainties have been reduced.

The Bootstrap Flywheel™

By Mike Hull • September 7, 2026
The Bootstrap Flywheel™ is a different model: use each small de-risking step to make the next step easier, cheaper, and more credible.

Biotech Funding Sequence: What Money Should You Raise First?

By Mike Hull • September 6, 2026
The most important financing question for an early biotech company is often not how much money to raise. It is what type of money should fund the next milestone.

When Should a Biotech Startup Raise Venture Capital?

By Mike Hull • September 5, 2026
Venture capital is not inherently too early or too expensive. It becomes expensive when founders use it to answer questions that could have been answered first with smaller or less dilutive resources.